TECENTRIQ®: SURVIVAL THAT ENDURES
Overall survival advantage demonstrated with TECENTRIQ 1-3
ADA=antidrug antibody; CI=confidence interval;
HR=hazard ratio; OS=overall survival; PD-L1=programmed death-ligand
*Stratified by PD-L1 expression in tumor-inflitrating immune cells, the number of prior chemotherapy regimens, and histology.
†Based on the stratified log-rank test.
- The Kaplan-Meier curves separated starting at approximately 3 months
Additional OS analyses 1
- In an interim analysis of all 1225 patients, median OS was 13.3 months with TECENTRIQ (95% CI, 11.3, 14.9) vs 9.8 months with docetaxel (95% CI, 8.9, 11.3) (HR=0.79; 95% CI, 0.69, 0.91; P=0.0013)
- Exploratory analyses showed that the subset of patients who were ADA positive by Week 4 (21%) appeared to have less efficacy (effect on OS) as compared to patients who tested negative for treatment-emergent ADA by Week 4 (79%). ADA-positive patients by Week 4 appeared to have similar OS compared to docetaxel-treated patients
Select Important Safety Information
Serious and sometimes fatal adverse reactions occurred with TECENTRIQ treatment. Warnings and precautions include immune-mediated serious adverse reactions, including pneumonitis, hepatitis, colitis, endocrinopathies, and other immune-mediated adverse reactions. Other warnings and precautions include infections, infusion-related reactions, and embryo-fetal toxicity.
PRESPECIFIED EXPLORATORY SUBGROUP ANALYSIS
Forest plot of overall survival in select patient subgroups 1,2
IC=tumor-infiltrating immune cell; ITT=intent to
treat; TC=tumor cell.
HR values were stratified for the ITT and TC or IC ≥1% subgroups. All other subgroup HR values were unstratified.
TECENTRIQ® DELIVERED ENDURING RESPONSE
Greater than 16 months median DoR with TECENTRIQ 1
Response rates and progression-free survival were similar between TECENTRIQ and docetaxel 1
- ORR was 14% with TECENTRIQ (95% CI, 11%, 17%) (58/425) vs 13% with docetaxel (95% CI, 10%, 17%) (57/425)
- Median PFS was
2.8 months with TECENTRIQ (95% CI, 2.6, 3.0) vs 4.0 months with
docetaxel (95% CI, 3.3, 4.2) (HR=0.95; 95% CI, 0.82, 1.10)
DoR=duration of response; NE=not estimable; ORR=overall response rate; PFS=progression-free survival.
IMPORTANT SAFETY INFORMATION AND INDICATION
TECENTRIQ is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving TECENTRIQ.
ALK=anaplastic lymphoma kinase; EGFR=epidermal growth factor receptor.
Serious Adverse Reactions
Please refer to the full Prescribing Information for important dose management information specific to adverse reactions.
- Immune-mediated pneumonitis or interstitial lung disease, including fatal cases, have occurred with TECENTRIQ treatment
- Across clinical trials, 2.5% of patients developed pneumonitis, including Grade 3 (0.6%), Grade 4 (0.1%), and Grade 5 (<0.1%) events
- Monitor patients for signs and symptoms of pneumonitis. Evaluate patients with suspected pneumonitis with radiographic imaging. Administer corticosteroids followed by a taper. Withhold TECENTRIQ for Grade 2 and permanently discontinue for Grade 3 or 4 pneumonitis
- Liver test abnormalities and immune-mediated hepatitis, including fatal cases, have occurred with TECENTRIQ treatment
- Across clinical trials, hepatitis occurred in 9% of patients, including Grade 3 (2.3%), Grade 4 (0.6%), and Grade 5 (<0.1%) events
- Monitor patients for signs and symptoms of hepatitis, during and after discontinuation of TECENTRIQ, including clinical chemistry monitoring. Administer corticosteroids followed by a taper for immune-mediated hepatitis. Withhold TECENTRIQ for AST or ALT elevations more than 3 and up to 8 times the upper limit of normal or total bilirubin more than 1.5 and up to 3 times the upper limit of normal. Permanently discontinue TECENTRIQ for AST or ALT elevations more than 8 times the upper limit of normal or total bilirubin more than 3 times the upper limit of normal
- Immune-mediated colitis or diarrhea have occurred with TECENTRIQ treatment
- Across clinical trials, diarrhea or colitis occurred in 20% of patients, including Grade 3 (1.4%) events
- Monitor patients for signs and symptoms of diarrhea or colitis. Withhold TECENTRIQ for Grade 2 or 3 and permanently discontinue for Grade 4 diarrhea or colitis
- TECENTRIQ can cause immune-mediated endocrinopathies, including thyroid disorders, adrenal insufficiency, and type 1 diabetes mellitus, including diabetic ketoacidosis, and hypophysitis/hypopituitarism
- Withhold TECENTRIQ for Grade 2 to 4 endocrinopathies
- Thyroid Disorders
- Across clinical studies, hypothyroidism occurred in 4.6% of patients and hyperthyroidism occurred in 1.6% of patients
- Monitor thyroid function prior to and during treatment with TECENTRIQ. Initiate hormone replacement therapy or medical management of hyperthyroidism as clinically indicated
- Adrenal Insufficiency
- Across clinical studies, adrenal insufficiency occurred in 0.4% of patients, including Grade 3 (<0.1%) events
- Monitor patients for clinical signs and symptoms of adrenal insufficiency. For Grade 2 to 4 adrenal insufficiency, initiate corticosteroids and hormone replacement therapy as clinically indicated
- Type 1 Diabetes Mellitus
- Across clinical studies, type 1 diabetes mellitus occurred in <0.1% of patients
- Monitor patients for hyperglycemia or other signs and symptoms of diabetes. Initiate treatment with insulin as clinically indicated
- Across clinical studies, Grade 2 hypophysitis occurred in <0.1% of patients
- For Grade 2 to 4 hypophysitis, initiate corticosteroids and hormone replacement therapy as clinically indicated
Other Immune-Mediated Adverse Reactions
- TECENTRIQ can cause severe and fatal immune-mediated adverse reactions. These immune-mediated reactions may involve any organ system
- Across clinical trials, cardiac, dermatologic, gastrointestinal, general, hematological, musculoskeletal, neurological, ophthalmological, renal, and vascular immune-mediated adverse reactions occurred at an incidence of <1% in patients who received TECENTRIQ or were reported for other products in this class of therapy
- For suspected Grade 2 immune-mediated adverse reactions, exclude other causes and initiate corticosteroids as clinically indicated. For severe (Grade 3 or 4) adverse reactions, withhold TECENTRIQ and administer corticosteroids. Permanently discontinue TECENTRIQ for Grade 4 immune-mediated adverse reactions involving a major organ
- TECENTRIQ can cause severe infections including fatal cases
- Across clinical trials, infections occurred in 42% of patients, including Grade 3 (8.7%), Grade 4 (1.5%), and Grade 5 (1%) events
- Monitor patients for signs and symptoms of infection. For Grade 3 or 4 infections, withhold TECENTRIQ and resume once clinically stable
- TECENTRIQ can cause severe or life-threatening infusion-related reactions
- Across clinical trials, infusion-related reactions occurred in 1.3% of patients, including Grade 3 (0.2%) events
- Monitor for signs and symptoms of infusion-related reactions. Interrupt or slow the rate of infusion in patients with Grade 1 or 2 infusion-related reactions. Permanently discontinue TECENTRIQ in patients with Grade 3 or 4 infusion-related reactions
- Based on its mechanism of action, TECENTRIQ can cause fetal harm when administered to a pregnant woman. Verify pregnancy status of females of reproductive potential prior to initiating TECENTRIQ. Advise females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TECENTRIQ and for at least 5 months after the last dose
- Because of the potential for serious adverse reactions in breastfed infants from TECENTRIQ, advise female patients not to breastfeed while taking TECENTRIQ and for at least 5 months after the last dose
- Based on animal studies, TECENTRIQ may impair fertility in females of reproductive potential while receiving treatment
Most Common Adverse Reactions
The most common adverse reactions in NSCLC (rate ≥20%) were fatigue (43.5%), decreased appetite (23.5%), dyspnea (22%), and cough (26.4%).